Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Can We Make Small Molecules Lean? Optimization of a Highly Lipophilic TarO Inhibitor.
Mandal M, Tan Z, Madsen-Duggan C, Buevich AV, Caldwell JP, Dejesus R, Flattery A, Garlisi CG, Gill C, Ha SN, Ho G, Koseoglu S, Labroli M, Basu K, Lee SH, Liang L, Liu J, Mayhood T, McGuinness D, McLaren DG, Wen X, Parmee E, Rindgen D, Roemer T, Sheth P, Tawa P, Tata J, Yang C, Yang SW, Xiao L, Wang H, Tan C, Tang H, Walsh P, Walsh E, Wu J, Su J. Mandal M, et al. Among authors: basu k. J Med Chem. 2017 May 11;60(9):3851-3865. doi: 10.1021/acs.jmedchem.7b00113. Epub 2017 Mar 29. J Med Chem. 2017. PMID: 28322556
Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.
McElroy WT, Tan Z, Basu K, Yang SW, Smotryski J, Ho GD, Tulshian D, Greenlee WJ, Mullins D, Guzzi M, Zhang X, Bleickardt C, Hodgson R. McElroy WT, et al. Among authors: basu k. Bioorg Med Chem Lett. 2012 Feb 1;22(3):1335-9. doi: 10.1016/j.bmcl.2011.12.080. Epub 2011 Dec 21. Bioorg Med Chem Lett. 2012. PMID: 22227212
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
Scott JD, DeMong DE, Greshock TJ, Basu K, Dai X, Harris J, Hruza A, Li SW, Lin SI, Liu H, Macala MK, Hu Z, Mei H, Zhang H, Walsh P, Poirier M, Shi ZC, Xiao L, Agnihotri G, Baptista MA, Columbus J, Fell MJ, Hyde LA, Kuvelkar R, Lin Y, Mirescu C, Morrow JA, Yin Z, Zhang X, Zhou X, Chang RK, Embrey MW, Sanders JM, Tiscia HE, Drolet RE, Kern JT, Sur SM, Renger JJ, Bilodeau MT, Kennedy ME, Parker EM, Stamford AW, Nargund R, McCauley JA, Miller MW. Scott JD, et al. Among authors: basu k. J Med Chem. 2017 Apr 13;60(7):2983-2992. doi: 10.1021/acs.jmedchem.7b00045. Epub 2017 Mar 16. J Med Chem. 2017. PMID: 28245354
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H, Miller M, Poulet FM, Scott JD, Smith MD, Yin Z, Zhou X, Parker EM, Kennedy ME, Morrow JA. Fell MJ, et al. Among authors: basu k. J Pharmacol Exp Ther. 2015 Dec;355(3):397-409. doi: 10.1124/jpet.115.227587. Epub 2015 Sep 25. J Pharmacol Exp Ther. 2015. PMID: 26407721
Total synthesis of (-)-okilactomycin.
Smith AB 3rd, Basu K, Bosanac T. Smith AB 3rd, et al. Among authors: basu k. J Am Chem Soc. 2007 Dec 5;129(48):14872-4. doi: 10.1021/ja077569l. Epub 2007 Nov 13. J Am Chem Soc. 2007. PMID: 17997560
Total syntheses of the assigned structures of lituarines B and C.
Smith AB 3rd, Duffey MO, Basu K, Walsh SP, Suennemann HW, Frohn M. Smith AB 3rd, et al. Among authors: basu k. J Am Chem Soc. 2008 Jan 16;130(2):422-3. doi: 10.1021/ja078293k. Epub 2007 Dec 21. J Am Chem Soc. 2008. PMID: 18095694 No abstract available.
289 results